|Bid Price||GBX 66.14||Offer Price||GBX 66.26|
|Mid Price||-||Day Change||GBX +0.01 (0.02%)|
|Price Date||15 Dec 2017||Crown Rating|
|Shares Class||Inc.||Yield||0.60 %|
|Total Expense Ratio||0.00||Fund Size||426,748,314.89|
|Launch Date||01/11/2000||Standard Initial Charge (%)||0.00|
|Annual Management Charge (%)||0.00||Sector||IMA UK Equity Income|
|Min Investment (£)||500.00||Total Expense Ratio (%)||0.00|
|ISIN||GB0001955532||Min TopUp (£)||100.00|
The objective of this fund is to provide growth by tracking the performance of those companies in the FTSE World Index which are engaged in Health, Pharmaceuticals and Biotechnology activities.The fund will invest almost entirely in company shares. The fund's investments will closely match those that make up the Index. The Index consists of company shares from around the world.The fund may use derivatives (contracts which have a value linked to the price of another asset) for the following purposes:•To help with efficient day to day management.•To reduce some of the risks of the market.If you hold accumulation units, income from investments held by the fund (dividends) will be reinvested into the value of your units.If you hold distribution units, income from investments held by the fund will be paid out to you (as a dividend).This fund may not be appropriate for investors who plan to withdraw their money within five years.
LGIM Index Fund Management Team
The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.